Literature DB >> 18923172

Clinical practice. Gastroesophageal reflux disease.

Peter J Kahrilas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18923172      PMCID： PMC3058591          DOI： 10.1056/NEJMcp0804684

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  54 in total

1.  The long term results of open antireflux surgery in a community-based health care center.

Authors:  T K Rantanen; T V Halme; M E Luostarinen; L M Karhumäki; E O Könönen; J O Isolauri
Journal:  Am J Gastroenterol       Date:  1999-07       Impact factor: 10.864

2.  Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk?

Authors:  L A Garcia Rodríguez; A Ruigómez
Journal:  Epidemiology       Date:  1997-09       Impact factor: 4.822

3.  Opposing time trends of peptic ulcer and reflux disease.

Authors:  H B el-Serag; A Sonnenberg
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

4.  High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial.

Authors:  P J Kahrilas; M B Fennerty; B Joelsson
Journal:  Am J Gastroenterol       Date:  1999-01       Impact factor: 10.864

5.  Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis.

Authors:  N Chiba; C J De Gara; J M Wilkinson; R H Hunt
Journal:  Gastroenterology       Date:  1997-06       Impact factor: 22.682

6.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.

Authors:  J Lagergren; R Bergström; A Lindgren; O Nyrén
Journal:  N Engl J Med       Date:  1999-03-18       Impact factor: 91.245

Review 7.  Effectiveness of proton pump inhibitors in nonerosive reflux disease.

Authors:  Bonnie B Dean; Anacleto D Gano; Kevin Knight; Joshua J Ofman; Ronnie Fass
Journal:  Clin Gastroenterol Hepatol       Date:  2004-08       Impact factor: 11.382

8.  Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects.

Authors:  P L Peghini; P O Katz; D O Castell
Journal:  Gastroenterology       Date:  1998-12       Impact factor: 22.682

9.  Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.

Authors:  T L Venables; R D Newland; A C Patel; J Hole; C Wilcock; M L Turbitt
Journal:  Scand J Gastroenterol       Date:  1997-10       Impact factor: 2.423

10.  Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group.

Authors:  S M Sabesin; R G Berlin; T J Humphries; D C Bradstreet; K L Walton-Bowen; S Zaidi
Journal:  Arch Intern Med       Date:  1991-12
View more
  84 in total

1.  Esophageal acid stimulation alters insular cortex functional connectivity in gastroesophageal reflux disease.

Authors:  R M Siwiec; A Babaei; M Kern; E A Samuel; S-J Li; R Shaker
Journal:  Neurogastroenterol Motil       Date:  2014-11-04       Impact factor: 3.598

2.  Comparison of presentation and impact on quality of life of gastroesophageal reflux disease between young and old adults in a Chinese population.

Authors:  Shou-Wu Lee; Chia-Ming Chang; Chi-Sen Chang; Ai-Wen Kao; Ming-Chih Chou
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

3.  Gastroesophageal reflux disease: Important considerations for the older patients.

Authors:  Maxwell M Chait
Journal:  World J Gastrointest Endosc       Date:  2010-12-16

4.  Effects of meal size and proximal-distal segmentation on gastric activity.

Authors:  Madileine-F Américo; Marjorie-V Ietsugu; Fernando-G Romeiro; Luciana-A Corá; Ricardo-B Oliveira; José-Ricardo-A Miranda
Journal:  World J Gastroenterol       Date:  2010-12-14       Impact factor: 5.742

5.  "War and Peace" with Barrett's esophagus.

Authors:  George Triadafilopoulos; Charles M Lombard; Blair A Jobe
Journal:  Dig Dis Sci       Date:  2011-04       Impact factor: 3.199

6.  Diagnosis and management of Barrett's esophagus for the endoscopist.

Authors:  Sagar S Garud; Steven Keilin; Qiang Cai; Field F Willingham
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

7.  Characterization and optimization of orodispersible mosapride film formulations.

Authors:  Aliaa N ElMeshad; Arwa S El Hagrasy
Journal:  AAPS PharmSciTech       Date:  2011-10-19       Impact factor: 3.246

8.  The LINX® reflux management system: confirmed safety and efficacy now at 4 years.

Authors:  John C Lipham; Tom R DeMeester; Robert A Ganz; Luigi Bonavina; Greta Saino; Daniel H Dunn; Paul Fockens; Willem Bemelman
Journal:  Surg Endosc       Date:  2012-04-27       Impact factor: 4.584

9.  The effect of antisecretory therapy and study duration on ambulatory esophageal pH monitoring.

Authors:  Vladimir M Kushnir; Gregory S Sayuk; C Prakash Gyawali
Journal:  Dig Dis Sci       Date:  2010-11-03       Impact factor: 3.199

10.  Early referral for esophageal pH monitoring is more cost-effective than prolonged empiric trials of proton-pump inhibitors for suspected gastroesophageal reflux disease.

Authors:  David A Kleiman; Toni Beninato; Brian P Bosworth; Laurent Brunaud; Thomas Ciecierega; Carl V Crawford; Brian G Turner; Thomas J Fahey; Rasa Zarnegar
Journal:  J Gastrointest Surg       Date:  2013-11-09       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.